Cancer Letters
Volume 236, Issue 2 , Pages 292-301 , 18 May 2006

Matrilysin over-expression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation

Received 6 March 2005 ,Revised 16 May 2005 ,Accepted 18 May 2005.

References 

  1. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer. 2002;2:657–672
  2. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer. 2002;99:157–166
  3. Egeblad M, Werb Z. Werb, New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer. 2002;2:161–174
  4. Gaire M, Magbanua Z, McDonnell S, McNeil L, Lovett DH, Matrisian LM. Structure and expression of the human gene for the matrix metalloproteinase matrilysin. J. Biol. Chem. 1994;269:2032–2040
  5. Shiomi T, Okada Y. MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev. 2003;22:145–152
  6. Masaki T, Matsuoka H, Sugiyama M, Abe N, Goto A, Sakamoto A, et al. Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. Br. J. Cancer. 2001;84:1317–1321
  7. Fingleton BM, Heppner KJ, Crawford HC, Matrisian LM. Matrilysin in early stage intestinal tumorigenesis. Apmis. 1999;107:102–110
  8. Hashimoto K, Yano A, Tanabe T, Usui T, Kihira Y, Matsuo Y. Localization and expression of matrix metalloproteinase-7 in human prostate. Nippon Hinyokika Gakkai Zasshi. 1997;88:852–857
  9. Hashimoto K, Kihira Y, Matuo Y, Usui T. Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate. J. Urol. 1998;160:1872–1876
  10. Knox JD, Wolf C, McDaniel K, Clark V, Loriot M, Bowden GT, et al. Matrilysin expression in human prostate carcinoma. Mol. Carcinog. 1996;15:57–63
  11. Adachi Y, Itoh F, Yamamoto H, Matsuno K, Arimura Y, Kusano M, et al. Matrix metalloproteinase matrilysin (MMP-7) participates in the progression of human gastric and esophageal cancers. Int. J. Oncol. 1998;13:1031–1035
  12. Ajisaka H, Yonemura Y, Miwa K. Correlation of lymph node metastases and expression of matrix metalloproteinase-7 in patients with gastric cancer. Hepatogastroenterology. 2004;51:900–905
  13. Honda M, Mori M, Ueo H, Sugimachi K, Akiyoshi T. Matrix metalloproteinase-7 expression in gastric carcinoma. Gut. 1996;39:444–448
  14. Kitoh T, Yanai H, Saitoh Y, Nakamura Y, Matsubara Y, Kitoh H, et al. Increased expression of matrix metalloproteinase-7 in invasive early gastric cancer. J. Gastroenterol. 2004;39:434–440
  15. Adachi Y, Yamamoto H, Itoh F, Arimura Y, Nishi M, Endo T, et al. Clinicopathologic and prognostic significance of matrilysin expression at the invasive front in human colorectal cancers. Int. J. Cancer. 2001;95:290–294
  16. Ichikawa Y, Ishikawa T, Momiyama N, Yamaguchi S, Masui H, Hasegawa S, et al. Detection of regional lymph node metastases in colon cancer by using RT-PCR for matrix metalloproteinase 7, matrilysin. Clin. Exp. Metastasis. 1998;16:3–8
  17. Ishikawa T, Ichikawa Y, Mitsuhashi M, Momiyama N, Chishima T, Tanaka K, et al. Matrilysin is associated with progression of colorectal tumor. Cancer Lett. 1996;107:5–10
  18. Zeng ZS, Shu WP, Cohen AM, Guillem JG. Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases. Clin. Cancer Res. 2002;8:144–148
  19. Sasaki H, Yukiue H, Moiriyama S, Kobayashi Y, Nakashima Y, Kaji M, et al. Clinical significance of matrix metalloproteinase-7 and Ets-1 gene expression in patients with lung cancer. J. Surg. Res. 2001;101:242–247
  20. Tanimoto H, Underwood LJ, Shigemasa K, Parmley TH, Wang Y, Yan Y, et al. The matrix metalloprotease pump-1 (MMP-7, Matrilysin): a candidate marker/target for ovarian cancer detection and treatment. Tumour. Biol. 1999;20:88–98
  21. Ohashi K, Nemoto T, Nakamura K, Nemori R. Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas. Cancer. 2000;88:2201–2209
  22. Birkedal-Hansen B, Pavelic ZP, Gluckman JL, Stambrook P, Li YQ, Stetler-Stevenson WG. MMP and TIMP gene expression in head and neck squamous cell carcinomas and adjacent tissues. Oral Dis. 2000;6:376–382
  23. Powell WC, Knox JD, Navre M, Grogan TM, Kittelson J, Nagle RB, et al. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res. 1993;53:417–422
  24. Witty JP, McDonnell S, Newell KJ, Cannon P, Navre M, Tressler RJ, et al. Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res. 1994;54:4805–4812
  25. Hasegawa S, Koshikawa N, Momiyama N, Moriyama K, Ichikawa Y, Ishikawa T, et al. Matrilysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model. Int. J. Cancer. 1998;76:812–816
  26. Miyazaki K, Koshikawa N, Hasegawa S, Momiyama N, Nagashima Y, Moriyama K, et al. Matrilysin as a target for chemotherapy for colon cancer: use of antisense oligonucleotides as antimetastatic agents. Cancer Chemother. Pharmacol. 1999;43(Suppl):S52–S55
  27. Momiyama N, Koshikawa N, Ishikawa T, Ichikawa Y, Hasegawa S, Nagashima Y, et al. Inhibitory effect of matrilysin antisense oligonucleotides on human colon cancer cell invasion in vitro. Mol. Carcinog. 1998;22:57–63
  28. Yonemura Y, Endo Y, Fujita H, Kimura K, Sugiyama K, Momiyama N, et al. Inhibition of peritoneal dissemination in human gastric cancer by MMP-7-specific antisense oligonucleotide. J. Exp. Clin. Cancer Res. 2001;20:205–212
  29. Pacheco MM, Mourao M, Mantovani EB, Nishimoto IN, Brentani MM. Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin. Exp. Metastasis. 1998;16:577–585
  30. Chung GG, Zerkowski MP, Ocal IT, Dolled-Filhart M, Kang JY, Psyrri A, et al. beta-Catenin and p53 analyses of a breast carcinoma tissue microarray. Cancer. 2004;100:2084–2092
  31. Hagemann T, Robinson SC, Schulz M, Trumper L, Balkwill FR, Binder C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis. 2004;25:1543–1549
  32. Binder C, Hagemann T, Husen B, Schulz M, Einspanier A. Relaxin enhances in-vitro invasiveness of breast cancer cell lines by up-regulation of matrix metalloproteases. Mol. Hum. Reprod. 2002;8:789–796
  33. Wang FQ, So J, Reierstad S, Fishman DA. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int. J. Cancer. 2004;114:19–31
  34. Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, et al. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc. Natl Acad. Sci. USA. 2002;99:16899–16903
  35. Zhao YG, Xiao AZ, Newcomer RG, Park HI, Kang T, Chung LW, et al. Activation of pro-gelatinase B by endometase/matrilysin-2 promotes invasion of human prostate cancer cells. J. Biol. Chem. 2003;278:15056–15064
  36. Barille S, Bataille R, Rapp MJ, Harousseau JL, Amiot M. Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation. J. Immunol. 1999;163:5723–5728
  37. Overbergh L, Valckx D, Waer M, Mathieu C. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine. 1999;11:305–312
  38. Wilson CL, Matrisian LM. Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int. J. Biochem. Cell. Biol. 1996;28:123–136
  39. Yamamoto H, Itoh F, Hinoda Y, Imai K. Suppression of matrilysin inhibits colon cancer cell invasion in vitro. Int. J. Cancer. 1995;61:218–222
  40. von Bredow DC, Cress AE, Howard EW, Bowden GT, Nagle RB. Activation of gelatinase-tissue-inhibitors-of-metalloproteinase complexes by matrilysin. Biochem. J. 1998;331(Pt 3):965–972
  41. Imai K, Yokohama Y, Nakanishi I, Ohuchi E, Fujii Y, Nakai N, et al. Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. J. Biol. Chem. 1995;270:6691–6697
  42. Wielockx B, Libert C, Wilson C. Matrilysin (matrix metalloproteinase-7): a new promising drug target in cancer and inflammation?. Cytokine Growth Factor Rev. 2004;15:111–115
  43. Wilson CL, Heppner KJ, Labosky PA, Hogan BL, Matrisian LM. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl Acad. Sci. USA. 1997;94:1402–1407
  44. Crawford HC, Scoggins CR, Washington MK, Matrisian LM, Leach SD. Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J. Clin. Invest. 2002;109:1437–1444

PII: S0304-3835(05)00496-9

doi: 10.1016/j.canlet.2005.05.042

Cancer Letters
Volume 236, Issue 2 , Pages 292-301 , 18 May 2006

Article Tools

* Image Usage & Resolution